• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Heron Therapeutics Inc.

    11/12/24 9:32:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRTX alert in real time by email
    SC 13G 1 p24-3088sc13g.htm HERON THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     

    Heron Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)
     

    427746102

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 42774610213GPage 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    8,850,000  

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    8,850,000  

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,850,000  

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.84%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

    CUSIP No. 42774610213GPage 3 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    8,850,000  

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    8,850,000  

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,850,000  

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.84%

    12

    TYPE OF REPORTING PERSON

    IN; HC

             

     

     

     

     

    CUSIP No. 42774610213GPage 4 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    8,850,000  

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    8,850,000  

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,850,000  

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.84%

    12

    TYPE OF REPORTING PERSON

    IN; HC

             

     

     

     

     

    CUSIP No. 42774610213GPage 5 of 8 Pages

     

     

    Item 1(a). NAME OF ISSUER
       
      The name of the issuer is Heron Therapeutics, Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
       
      The Company’s principal executive offices are located at 4242 Campus Point Court, Suite 200, San Diego, CA 92121.

     

    Item 2(a). NAME OF PERSON FILING
       
      This statement is filed by:

     

      (i) Adage Capital Management, L.P., a Delaware limited partnership (“ACM”), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership (“ACP”), with respect to the shares of Common Stock directly held by ACP;
       
      (ii) Robert Atchinson (“Mr. Atchinson”), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACA”), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACPGP”), general partner of ACP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company (“ACPLLC”), general partner of ACM, with respect to the shares of Common Stock directly held by ACP; and
       
      (iii) Phillip Gross (“Mr. Gross”), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the shares of Common Stock directly held by ACP.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP
       
      ACM is a limited partnership organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      Common Stock, par value $0.01 per share (the “Common Stock”).

     

     

    CUSIP No. 42774610213GPage 6 of 8 Pages

     

     

    Item 2(e). CUSIP NUMBER
       
      427746102

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) þ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) þ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable.                                                             

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The percentage set forth in this Schedule 13G is calculated based upon 151,668,017 shares of Common Stock outstanding as of August 1, 2024, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 6, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
       
      Not applicable.

     

     

    CUSIP No. 42774610213GPage 7 of 8 Pages

     

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      See Item 2(a).

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      Not applicable.

     

    Item 10. CERTIFICATION  
         
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 42774610213GPage 8 of 8 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 12, 2024

     

    ADAGE CAPITAL MANAGEMENT, L.P.  
    By: Adage Capital Partners LLC,  
    its general partner  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    /s/ Robert Atchinson  
    ROBERT ATCHINSON, individually  
       
    /s/ Phillip Gross  
    PHILLIP GROSS, individually  

     

     

    Get the next $HRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HRTX

    DatePrice TargetRatingAnalyst
    6/13/2024$7.00Buy
    Rodman & Renshaw
    4/23/2024$6.00Overweight
    CapitalOne
    3/13/2024$4.00 → $5.00Buy
    Needham
    More analyst ratings

    $HRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

      Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

      11/22/24 4:36:11 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for APONVIE issued to HERON THERAPS INC

      Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling

      3/11/24 4:38:31 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for CINVANTI issued to HERON THERAPS INC

      Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling

      3/11/24 4:38:29 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    SEC Filings

    See more
    • SEC Form S-8 filed by Heron Therapeutics Inc.

      S-8 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)

      5/6/25 5:00:45 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Heron Therapeutics Inc.

      10-Q - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)

      5/6/25 7:45:21 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)

      5/6/25 7:45:11 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Financials

    Live finance-specific insights

    See more
    • Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

      Generated Q1 2025 Net Revenue of $38.9 millionDelivered record Q1 2025 Adjusted EBITDA of $6.2 millionReached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI® and APONVIE® patent litigations, including an agreed market entry date of June 1, 2032Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates. "We are off to a strong start in 2025, achieving record adjusted EBITDA for the firs

      5/6/25 7:45:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

      CARY, N.C., April 22, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, May 6, 2025, at 8:00 a.m. ET to report first quarter 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Invest

      4/22/25 4:05:00 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

      Achieved Q4 2024 GAAP Net Income of $3.6 millionGenerated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-yearDelivered full-year 2024 adjusted EBITDA of $8.6 millionGenerated ZYNRELEF® Q4 2024 Net Revenue of $8.5 million and launched the ZYNRELEF Vial Access Needle ("VAN") in December 2024U.S. District Court ruled in favor of Heron in patent lawsuit against Fresenius Kabi USA, LLC, and upheld the validity of CINVANTI® patents which expire in 2035 CARY, N.C., Feb. 27, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 3

      2/27/25 7:45:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Heron Therapeutics Inc.

      SC 13G - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

      11/12/24 9:32:11 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Heron Therapeutics Inc. (Amendment)

      SC 13D/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

      5/31/24 11:08:56 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Heron Therapeutics Inc. (Amendment)

      SC 13G/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

      2/14/24 4:37:34 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Forbes William P bought $27,250 worth of shares (25,000 units at $1.09), increasing direct ownership by 46% to 79,000 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      11/21/23 12:19:26 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forbes William P bought $46,995 worth of shares (50,000 units at $0.94), increasing direct ownership by 1,250% to 54,000 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      11/20/23 10:07:28 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collard Craig A bought $137,970 worth of shares (150,000 units at $0.92), increasing direct ownership by 411% to 186,496 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      11/17/23 12:37:52 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Heron Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $7.00

      6/13/24 7:14:56 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Heron Therapeutics with a new price target

      CapitalOne initiated coverage of Heron Therapeutics with a rating of Overweight and set a new price target of $6.00

      4/23/24 6:55:56 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Heron Therapeutics with a new price target

      Needham reiterated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $5.00 from $4.00 previously

      3/13/24 7:55:22 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

      CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. "I am excited to welcome Mark to Heron as our new Chief Operating Officer," said Craig Collard, Chief Executive Officer of Heron. "Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficienc

      4/28/25 6:55:00 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

      SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Mr. Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Thera

      11/4/24 5:00:00 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

      SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management team enabling the next phase of growth. "Now is the right time to add substantial BD and M&A experience to the management team at Heron, and I welcome Brett to

      9/3/24 8:00:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

      Generated Q1 2025 Net Revenue of $38.9 millionDelivered record Q1 2025 Adjusted EBITDA of $6.2 millionReached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI® and APONVIE® patent litigations, including an agreed market entry date of June 1, 2032Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates. "We are off to a strong start in 2025, achieving record adjusted EBITDA for the firs

      5/6/25 7:45:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

      — Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 — CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve the ongoing patent litigations between the parties in the U.S. District Court for the District of Delaware related to CINVANTI® (aprepitant) injectable emulsion and APONVIE® (aprepitant) injectable emulsion. Pursuant to the terms of the settlement agreement, the Company has granted Mylan a license under

      5/6/25 7:30:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

      CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. "I am excited to welcome Mark to Heron as our new Chief Operating Officer," said Craig Collard, Chief Executive Officer of Heron. "Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficienc

      4/28/25 6:55:00 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Hensley Mark Earl

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      5/7/25 12:20:50 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Development Officer Forbes William P converted options into 11,694 shares, increasing direct ownership by 11% to 122,566 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      5/2/25 8:41:15 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Financial Officer Duarte Ira converted options into 11,694 shares, increasing direct ownership by 9% to 136,149 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      5/2/25 8:32:09 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care